Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01681992
Other study ID # 115649
Secondary ID 2011-004905-26
Status Completed
Phase Phase 3
First received
Last updated
Start date October 10, 2012
Est. completion date August 18, 2015

Study information

Verified date December 2020
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck & Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).


Description:

This trial is a Phase IIIA, randomized, observer-blind, controlled, multi-center, multi-country study with four parallel groups. This study will evaluate the immunogenicity and safety of GSK Biologicals' trivalent investigational MMR vaccine (referred to as Inv_MMR vaccine, throughout this document) in contrast to the US standard of care comparator vaccine (M-M-R II, Merck and Co., Inc., referred to as Com_MMR throughout this document) in children during their second year of life. The first dose of this two-dose study is designed to establish the end of shelf-life potency of Inv_MMR vaccine. The Inv_MMR vaccine will be given as one of two lots; one of a minimum potency, designated Inv_MMR_Min; and the other at a mid-range or medium potency designated Inv_MMR_Med to two groups. The second dose for both of these Inv_MMR groups will have a potency within the release range of the marketed vaccine. The Com_MMR vaccine will consist of two lots designated Com_MMR_L1 and Com_MMR_L2 and will be analyzed as pooled lots within the study. The first MMR vaccine dose will be co-administered with Varivax, Havrix and (in the US sub-cohort only) Prevnar 13 which are routinely administered to children of this age in the US.


Recruitment information / eligibility

Status Completed
Enrollment 4538
Est. completion date August 18, 2015
Est. primary completion date February 3, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 15 Months
Eligibility Inclusion Criteria: - Male or female child between 12 and 15 months of age at the time of vaccination. - The investigator believes that the parent(s) or Legally Acceptable Representative(s) (LAR(s)) of the child, can, and will comply with the requirements of the protocol. - Written informed consent obtained from the parent(s)/LAR(s) of the child. - Child is in stable health as determined by investigator's clinical examination and assessment of child's medical history. For US children only: • Child that previously received a 3-dose series of Prevnar 13 with last dose at least 60 days prior to study entry. Exclusion Criteria: - Child in care. - Use of any investigational or non-registered product other than the study vaccine(s) during the period starting 30 days before the day of study vaccination or planned use during the entire study period. - Concurrently participating in another clinical study, in which the child has been or will be exposed to an investigational or a non-investigational product. Chronic administration of immunosuppressants, or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose or any planned administration of immunosuppressive and immune-modifying drugs during the entire study. - Inhaled and topical steroids are allowed. - Planned administration / administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination at Visit 1 and ending at Visit 2 (or ending at Visit 3 for the US post-dose 2 sub-cohort). Please Note: - Inactivated influenza (Flu) vaccine and Haemophilus influenzae type b conjugate vaccine (Hib) vaccines may be given at any time during the study, including the day of study vaccination (Flu and Hib vaccines must be administered at a different location than the study vaccine/s). - Any age appropriate vaccine may be given starting at Visit 2 (or starting at Visit 3 for the US post-dose 2 sub-cohort), and anytime thereafter. - Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to study vaccination at Visit 1 or planned administration from the date of vaccination through the immunogenicity evaluation at Visit 2, or at Visit 3 for the US post-dose 2 sub-cohort. - History of measles, mumps, rubella, varicella/zoster and/or hepatitis A diseases. - Known exposure to measles, mumps, rubella and/or varicella/zoster during the period starting 30 days prior to the first study vaccination. - Previous vaccination against measles, mumps, rubella, hepatitis A and/or varicella virus. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. - A family history of congenital or hereditary immunodeficiency. - History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including hypersensitivity to neomycin, latex or gelatin. - Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. - Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as temperature =38°C/100.4°F by any age appropriate route. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection without fever. - Active untreated tuberculosis based on medical history. - Any other condition which, in the opinion of the Investigator, prevents the child from participating in the study. For US children only: • A child that previously received a fourth dose of any pneumococcal conjugate vaccine.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Priorix
Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
M-M-R II
Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
Varivax
Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
Havrix
Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
Prevnar 13
US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.

Locations

Country Name City State
Czechia GSK Investigational Site Benesov
Czechia GSK Investigational Site Chlumec nad Cidlinou
Czechia GSK Investigational Site Decin
Czechia GSK Investigational Site Jindrichuv Hradec
Czechia GSK Investigational Site Kladno
Czechia GSK Investigational Site Liberec
Czechia GSK Investigational Site Lipnik nad Becvou
Czechia GSK Investigational Site Nachod
Czechia GSK Investigational Site Odolena voda
Czechia GSK Investigational Site Ostrava - Poruba
Czechia GSK Investigational Site Pardubice
Czechia GSK Investigational Site Praha 6
Finland GSK Investigational Site Helsinki
Finland GSK Investigational Site Helsinki
Finland GSK Investigational Site Jarvenpaa
Finland GSK Investigational Site Oulu
Finland GSK Investigational Site Tampere
Finland GSK Investigational Site Turku
Malaysia GSK Investigational Site Kuala Terengganu
Malaysia GSK Investigational Site Kuching
Malaysia GSK Investigational Site Sibu
Puerto Rico GSK Investigational Site Guayama
Puerto Rico GSK Investigational Site Ponce
Puerto Rico GSK Investigational Site San Juan
Spain GSK Investigational Site Antequera/Málaga
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Centelles (Barcelona)
Spain GSK Investigational Site L'Eliana, Valencia
Spain GSK Investigational Site Manlleu
Spain GSK Investigational Site Quart De Poblet, Valencia
Spain GSK Investigational Site Santiago de Compostela
Spain GSK Investigational Site Sevilla
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Vic
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Chiang mai
Thailand GSK Investigational Site Pathum Thani
United States GSK Investigational Site Altamonte Springs Florida
United States GSK Investigational Site Annapolis Maryland
United States GSK Investigational Site Baltimore Maryland
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Charleston South Carolina
United States GSK Investigational Site Charleston South Carolina
United States GSK Investigational Site Cleveland Ohio
United States GSK Investigational Site Clyde North Carolina
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Ellensburg Washington
United States GSK Investigational Site Frederick Maryland
United States GSK Investigational Site Gresham Oregon
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Johnstown Pennsylvania
United States GSK Investigational Site Jonesboro Arkansas
United States GSK Investigational Site Kansas City Missouri
United States GSK Investigational Site Layton Utah
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Lincoln Nebraska
United States GSK Investigational Site Little Rock Arkansas
United States GSK Investigational Site Louisville Kentucky
United States GSK Investigational Site Miami Florida
United States GSK Investigational Site Miami Lakes Florida
United States GSK Investigational Site Midlothian Virginia
United States GSK Investigational Site Muncie Indiana
United States GSK Investigational Site Naples Florida
United States GSK Investigational Site New Albany Indiana
United States GSK Investigational Site Omaha Nebraska
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Richmond Virginia
United States GSK Investigational Site Saint George Utah
United States GSK Investigational Site Springville Utah
United States GSK Investigational Site Tampa Florida
United States GSK Investigational Site Toledo Ohio
United States GSK Investigational Site West Covina California
United States GSK Investigational Site West Des Moines Iowa
United States GSK Investigational Site Wichita Kansas
United States GSK Investigational Site Youngstown Ohio

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Czechia,  Finland,  Malaysia,  Puerto Rico,  Spain,  Thailand, 

References & Publications (1)

MMR-161 Study Group. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. Vaccine. 2018 Sep 11;36(38):5781-5788. doi: 10.1016/j.vaccine.2018.07.076. Epub 2018 Aug 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA]) For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration equal or above [=] 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration less than [<] 150 mIU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for measles virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be = 90% for antibodies to measles virus. At Day 42
Primary Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration = 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for mumps virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be = 90% for antibodies to mumps virus. At Day 42
Primary Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by Plaque Reduction Neutralization Test [PRNT]) For mumps virus as measured by PRNT, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration = 4 End point Dilution 50% (ED50) (PRNT) among subjects who were seronegative (antibody concentration < 2.5 ED50) before dose 1. At Day 42
Primary Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration = 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for rubella virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be = 90% for antibodies to mumps virus. At Day 42
Primary Anti-measles Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. At Day 42
Primary Anti-mumps Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as GMCs in EU/mL. At Day 42
Primary Anti-mumps Virus Antibody Concentrations (by PRNT) Antibody concentrations were expressed as Geometric Mean Titers (GMTs). At Day 42
Primary Anti-rubella Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as GMCs in IU/mL. At Day 42
Secondary Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration = 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration < 150 mIU/mL) before dose 1. At Day 84
Secondary Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration = 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1. At Day 84
Secondary Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value (by ELISA) For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration = 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1. At Day 84
Secondary Anti-measles Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as GMCs in mIU/mL. At Day 84
Secondary Anti-mumps Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as GMCs in EU/mL. At Day 84
Secondary Anti-rubella Virus Antibody Concentrations (by ELISA) Antibody concentrations were expressed as GMCs in IU/mL. At Day 84
Secondary Number of Subjects With Any Solicited Local Adverse Events (AEs) Post Dose 1 Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 4-day (Days 0-3) post-vaccination period
Secondary Number of Subjects With Any Solicited Local AEs Post Dose 2 Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 4-day (Days 0-3) post-vaccination period
Secondary Number of Subjects With Any Solicited General AEs Post Dose 1 Assessed solicited general AEs were drowsiness, irritability/fussiness and loss of appetite. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 15-day (Days 0-14) post-vaccination period
Secondary Number of Subjects Reporting Any Fever Post Dose 1 Any fever = Fever (axillary) = 38°C. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any Fever Post Dose 2 Any fever = Fever (axillary) = 38°C. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any Rash Post Dose 1 Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any Rash Post Dose 2 Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any MMR Specific Solicited General AEs Post Dose 1 Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any MMR Specific Solicited General AEs Post Dose 2 Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any Unsolicited AES Post Dose 1 Unsolicited AE was defined as any AE reported in reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any Unsolicited AES Post Dose 2 Unsolicited AE was defined as any AE reported in reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. During the 43-day (Days 0-42) post-vaccination period
Secondary Number of Subjects Reporting Any AEs of Specific Interest AEs of specific interest included new onset chronic disease (NOCD) (e.g., autoimmune disorders, asthma, type I diabetes, vasculitis, celiac disease, conditions associated with sub-acute or chronic thrombocytopenia and allergies) and AEs prompting emergency room (ER) visits. From Day 0 through the end of the study (Day 222)
Secondary Number of Subjects Reporting Any Serious Adverse Events (SAEs) SAEs assessed include any untoward medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity. From Day 0 through the end of the study (Day 222)
See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4
Completed NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Phase 2/Phase 3